The variable levels of the miRNA molecules as well as the DNA methylation profile of the SOX18 and SOX30 promoters can be detected in the patient’s blood, which additionally increases the availability and universality of their use in the diagnosis of lung cancer, as they provide information not only on the type of tumor, but also on the development stage. Here, SOX30 is linked to neoplasm.